CANCER IMMUNOTHERAPY

被引：0

作者：

Quintin-Colonna, Francoise ^{[1
]}

Montier, Yves ^{[1
]}

Pere, Helene ^{[1
]}

Sandoval, Federico ^{[1
]}

Merillon, Nathalie ^{[1
]}

Freyburger, Ludovic ^{[1
]}

Adotevi, Olivier ^{[1
]}

Tartour, Eric ^{[1
,2
]}

机构：

[1] Univ Paris 05, Ecole Natl Vet Alfort, EA 4054, F-94704 Maisons Alfort, France

[2] Hop Europeen Georges Pompidou, AP HP, Unite Immunol Biol, Paris, France

来源：

BULLETIN DE L ACADEMIE VETERINAIRE DE FRANCE | 2009年 / 162卷 / 4-5期

关键词：

cancer; antibodies; cytokines; cancer vaccine; DENDRITIC CELLS; MALIGNANT-MELANOMA; ANTITUMOR IMMUNITY; B-SUBUNIT; PHASE-II; TUMOR; VACCINES; INTERLEUKIN-2; LYMPHOCYTES; ANTIGEN;

D O I：

暂无

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

Tumor cells are recognized by the immune system, which controls the growth of some immunogenic tumors. Cancer immunotherapy is based on the stimulation of this natural defence against cancer. The use of recombinant cytokines (IL-2, IFN alpha...) and especially of antibodies has demonstrated the clinical efficacy of this approach. New immunotherapeutic strategies are being developed, based on the induction of anti-tumor T lymphocytes by cancer vaccines. The optimization of these vaccines is based on their validation in relevant preclinical and clinical models (spontaneous tumors in rodents and carnivore), on their association with molecules able to inhibit the resistance mechanisms of tumours to immunotherapy, and on more clearly defined clinical indications.

引用

页码：363 / 370

页数：8

共 36 条

[1] B subunit of Shiga toxin-based Vaccines synergize with α-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity [J].

Adotevi, Olivier ;

Vingert, Benoit ;

Freyburger, Ludovic ;

Shrikant, Protul ;

Lone, Yu-Chun ;

Quintin-Colonna, Francoise ;

Haicheur, Nacilla ;

Amessou, Mohamed ;

Herbelin, Andre ;

Langlade-Demoyen, Pierre ;

Fridman, Wolf H. ;

Lemonnier, Francois ;

Johannes, Ludger ;

Tartour, Eric .

JOURNAL OF IMMUNOLOGY, 2007, 179 (05) :3371-3379

[2] Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma [J].

Alexander, AN ;

Huelsmeyer, MK ;

Mitzey, A ;

Dubielzig, RR ;

Kurzman, ID ;

MacEwen, EG ;

Vail, DM .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (04) :433-442

[3] Phenotypic and functional analysis of T lymphocytes in cancer patients. [J].

Badoual, C ;

Vingert, B ;

Agueznay, N ;

Adotevi, O ;

Haicheur, N ;

Molina, T ;

Bruneval, P ;

Fridman, WH ;

Tartour, E .

ANNALES DE PATHOLOGIE, 2005, 25 (03) :211-219

[4]

Benchetrit F, 2003, B CANC, V90, P1

[5] Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients [J].

Bercovici, Nadege ;

Haicheur, Nacilla ;

Massicard, Severine ;

Vernel-Pauillac, Fredcrique ;

Adotevi, Olivier ;

Landais, Didier ;

Gorin, Isabelle ;

Robert, Caroline ;

Prince, H. Miles ;

Grob, Jean-Jacques ;

Leccia, Marie Therese ;

Lesimple, Thierry ;

Wijdenes, John ;

Bartholeyns, Jacques ;

Fridman, Wolf H. ;

Salcedo, Margarita ;

Ferries, Estelle ;

Tartour, Eric .

JOURNAL OF IMMUNOTHERAPY, 2008, 31 (01) :101-112

[6] Immune-potentiating effects chemotherapeutic drug of the cyclophosphamide [J].

Brode, Sven ;

Cooke, Anne .

CRITICAL REVIEWS IN IMMUNOLOGY, 2008, 28 (02) :109-126

[7] Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? [J].

Bui, Jack D. ;

Schreiber, Robert D. .

CURRENT OPINION IN IMMUNOLOGY, 2007, 19 (02) :203-208

[8]

Cann SAH, 2003, POSTGRAD MED J, V79, P672

[9]

Carcelain G, 1997, INT J CANCER, V72, P241, DOI 10.1002/(SICI)1097-0215(19970717)72:2<241::AID-IJC7>3.0.CO

[10]

2-R

← 1 2 3 4 →